Literature DB >> 16651632

Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies.

Mariana Rodríguez Zubieta1, David Furman, Marcela Barrio, Alicia Inés Bravo, Enzo Domenichini, José Mordoh.   

Abstract

The immune system recognizes diverse melanoma antigens. However, tumors can evade the immune response, therefore growing and progressing. It has been reported that galectin-3 and galectin-1 can induce apoptosis of activated lymphocytes. However, there is strong evidence indicating that the regulation of galectins function in the human tumor microenvironment is a complex process that is influenced by diverse biological circumstances. Here, we have investigated 33 biopsies (eight primary and 25 metastases) from 24 melanoma patients (15-72 years old) and describe the correlation between the expression of galectin-3 or galectin-1 and the level of apoptosis of tumor-associated lymphocytes using immunohistochemistry and an in situ nick translation assay. The range of galectin-3-positive tumor cells varied between 0% and 93% and that of galectin-1-positive tumor cells varied between 5% and 97%. In addition, 23 +/- 27% of tumor-associated lymphocytes were apoptotic. Although our results show a correlation between galectin-3 expression and apoptosis of tumor-associated lymphocytes, we could not find such correlation with galectin-1. Considering the complex process of cancer immunoediting, various interacting factors must be considered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16651632      PMCID: PMC1606586          DOI: 10.2353/ajpath.2006.050971

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  Galectin-3 induces endothelial cell morphogenesis and angiogenesis.

Authors:  P Nangia-Makker; Y Honjo; R Sarvis; S Akahani; V Hogan; K J Pienta; A Raz
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Authors:  V Shankaran; H Ikeda; A T Bruce; J M White; P E Swanson; L J Old; R D Schreiber
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

3.  Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis.

Authors:  K Okada; K Komuta; S Hashimoto; S Matsuzaki; T Kanematsu; T Koji
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

4.  Cancer statistics, 2000.

Authors:  R T Greenlee; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  2000 Jan-Feb       Impact factor: 508.702

5.  Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest.

Authors:  Tadashi Yoshii; Tomoharu Fukumori; Yuichiro Honjo; Hidenori Inohara; Hyeong-Reh Choi Kim; Avraham Raz
Journal:  J Biol Chem       Date:  2001-11-27       Impact factor: 5.157

6.  CD45 modulates galectin-1-induced T cell death: regulation by expression of core 2 O-glycans.

Authors:  J T Nguyen; D P Evans; M Galvan; K E Pace; D Leitenberg; T N Bui; L G Baum
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

7.  CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death.

Authors:  K E Pace; H P Hahn; M Pang; J T Nguyen; L G Baum
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

8.  Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.

Authors:  Steven A Rosenberg; Mark E Dudley
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-20       Impact factor: 11.205

9.  Galectin-3 surface expression on human adult chondrocytes: a potential substrate for collagenase-3.

Authors:  M Guévremont; J Martel-Pelletier; C Boileau; F-T Liu; M Richard; J-C Fernandes; J-P Pelletier; P Reboul
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

10.  Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion.

Authors:  L Ferradini; A Mackensen; C Genevée; J Bosq; P Duvillard; M F Avril; T Hercend
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

View more
  22 in total

1.  Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack.

Authors:  Wei Wang; Huaijian Guo; Jianlin Geng; Xiaodong Zheng; Haiming Wei; Rui Sun; Zhigang Tian
Journal:  J Biol Chem       Date:  2014-10-14       Impact factor: 5.157

2.  Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity.

Authors:  Gordana Radosavljevic; Ivan Jovanovic; Ivana Majstorovic; Maja Mitrovic; Vanda Juranic Lisnic; Nebojsa Arsenijevic; Stipan Jonjic; Miodrag L Lukic
Journal:  Clin Exp Metastasis       Date:  2011-03-26       Impact factor: 5.150

Review 3.  The roles of Galectin-3 in autoimmunity and tumor progression.

Authors:  Gordana Radosavljevic; Vladislav Volarevic; Ivan Jovanovic; Marija Milovanovic; Nada Pejnovic; Nebojsa Arsenijevic; Daniel K Hsu; Miodrag L Lukic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

4.  Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.

Authors:  Bonnie E Gould Rothberg; David L Rimm
Journal:  J Invest Dermatol       Date:  2010-06-17       Impact factor: 8.551

Review 5.  Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation.

Authors:  Gabriel A Rabinovich; Marta A Toscano
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

6.  Tumor-associated galectin-3 modulates the function of tumor-reactive T cells.

Authors:  Weiyi Peng; Helen Y Wang; Yoshihiro Miyahara; Guangyong Peng; Rong-Fu Wang
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

7.  Proteome serological determination of tumor-associated antigens in melanoma.

Authors:  Michael Forgber; Uwe Trefzer; Wolfram Sterry; Peter Walden
Journal:  PLoS One       Date:  2009-04-17       Impact factor: 3.240

Review 8.  Lessons from cancer immunoediting in cutaneous melanoma.

Authors:  Mariana Aris; María Marcela Barrio; José Mordoh
Journal:  Clin Dev Immunol       Date:  2012-08-14

9.  The IL-10 and IFN-gamma pathways are essential to the potent immunosuppressive activity of cultured CD8+ NKT-like cells.

Authors:  Li Zhou; Hongjie Wang; Xing Zhong; Yulan Jin; Qing-Sheng Mi; Ashok Sharma; Richard A McIndoe; Nikhil Garge; Robert Podolsky; Jin-Xiong She
Journal:  Genome Biol       Date:  2008-07-29       Impact factor: 13.583

Review 10.  Melanoma biomolecules: independently identified but functionally intertwined.

Authors:  Danielle E Dye; Sandra Medic; Mel Ziman; Deirdre R Coombe
Journal:  Front Oncol       Date:  2013-09-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.